Company intelligence / Profile preview

LEAH Labs

Eagan, Minnesota, United States

Ownership: Private
Employees: ~2
Development stage: Other

Overview

LEAH Labs has demonstrated early clinical success using gene-edited human CAR-T cell therapy to induce remissions in dogs with lymphoma. Results from the first two clinical trials indicate restoration of quality of life in canine patients, with ongoing monitoring and live imaging in partnership with academic veterinary centers. Over $1.5 million in SBIR and NIH/NSF support secured since 2022, enabling further clinical development and manufacturing scale-up.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapyGene therapyBiologic
Industry: Veterinary

Partnerships

Wilson Wolf ManufacturingBio-TechneCellReadyUniversity of Missouri College of Veterinary Medicine

Beyond the preview

Go deeper on LEAH Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LEAH Labs.

Explore the full profile